• U.S. commercial launch commenced with Rady Children's Hospital-San Diego as the first customer
• FDA cleared pediatric label expansions for NorthStar and Vision-MR Diagnostic Catheter
• Several additional U.S. hospitals in the final stages of purchasing
• Completed A$60m placement at A$1.85 per CDI
• Q2 CY2026 revenue of US$60.5k

Imricor Medical Systems, Inc. (ASX: IMR) released its Q2 CY2026 Quarterly Activities Report, marking significant milestones in its U.S. commercial launch. Rady Children's Hospital-San Diego became the first U.S. customer, purchasing NorthStar to establish a radiation-free cardiac catheterization program. The FDA cleared pediatric label expansions for NorthStar and the Vision-MR Diagnostic Catheter, enabling use in patients of all ages. Several additional U.S. hospitals are in the final stages of purchasing, with revenue from initial NorthStar sales expected to exceed total revenue generated by the European business in CY2025. The company completed a A$60m placement at A$1.85 per CDI, strengthening its balance sheet. Q2 CY2026 revenue was US$60.5k, with operating cash outflow of approximately US$6.1m.

Q2 CY2026 revenue of US$60.5k

The second half of CY2026 will focus on executing the U.S. commercial launch, completing the VISABL-AFL enrolment, and securing additional FDA clearances.